NewsRx

Search our medical news database

Hepatitis C Virus

Cyplasin Biomedical Announces migration to OTC Link Exchange

Published in Vaccine Weekly, March 23rd, 2011

2011 MAR 23 -- Cyplasin Biomedical Ltd.,(OTCQB: CPBM) (Frankfurt XYI1:FRA) is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market announced its shares are now being exclusively quoted on OTC Markets Group's OTC Link™ platform.

This change was not caused by any action or inaction by Cyplasin, which continues to be in full compliance with all of its U.S. Securities and Exchange Commission (SEC) reporting requirements. OTC Link is the world's largest interdealer quotation system for broker-dealers. Launched in 2010, OTCQB® was created to allow investors to...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook